An approach to Improve Therapeutic Efficacy of Doxycycline Hyclate in Treatment of Periodontitis

Ashish Prakash Gorle* and Dinesh Pannalal Khairnar

Department of Pharmaceutics R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist: Dhule (M.S.) India.

Abstract

A number of ways have been investigated for administration of antibacterial agents in dealing with plaque-initiated periodontal disease. These include prolonged release intrapocket devices which are inserted at diseased sites. Intrapocket drug delivery system was designed which contain Doxycycline Hyclate; an antibacterial agent. The formulations were so developed with an aim to reduce the dose of a drug, to target the drug to the specific site and to maintain dosage at its absorption site for an extended period of time thereby improves the patient compliance. The study was aimed towards by formulating the periodontal in situ gels by temperature induced gelation technique with the utilization of polymer Pluronic F127 which is synthetically prepared. The Pluronic F127 showed the sol-gel transition phenomenon in between 27-37 °C. In situ gels were prepared and characterized/evaluated for its physico-chemical properties such as pH, gelation properties, rheology, gel strength, mucoadhesion, drug content, in-vitro, and ex-vivo drug release rate, texture analysis and Differential Scanning Colorimetry etc. The formulation found to be solution at room temperature and forms gel after installation into periodontal pocket hence leading to increase in retention time and to slowly release the drug into pocket. The results of characterization of formulation were found to be satisfactory and hence significant bioavailability can be increased, so these in situ gelling systems will be useful in future for improving therapeutic efficacy of Doxycycline hyclate in treatment of Periodontitis. Owing to these properties it can be used as an effective delivery system for the intrapocket route.

Keywords: Doxycycline Hyclate; Pluronic F127; In Situ –Gel; Physical Characterization.

Introduction

Dental diseases are among the most widespread chronic disorders affecting mankind. The high incidence of carries and periodontal diseases is borne out by epidemiological studies carried out in many parts of the world. Compared to the widespread use of drugs for treating many medical conditions, relatively little use has been made of such forms of therapies in dental settings. Although employed to allay pain and anxiety and with the exceptions of fluoride, drugs have not been extensively used for treating dental diseases. Periodontal diseases are groups of infections and inflammatory conditions, including gingivitis and periodontitis that affect teeth supporting structures. These diseases occur when bacteria from dental plaque invade surrounding tissues and from the accumulation of plaque at the gingival margin, which, in turn, induces an inflammatory response (1).

The most common form of periodontal disease is referred to as chronic periodontal
disease describing a group of related inflammatory reactions resulting in destruction of the tissues that support tooth in its pocket. There are several types of periodontal diseases (periodontitis) which include chronic periodontitis, aggressive periodontitis, systemic disease associated periodontitis, and necrotizing periodontitis. The clinical signs of periodontitis are changed in the morphology of gingival tissue, bleeding upon probing as well as periodontal pocket formation. This pocket provides an ideal environment for the growth and proliferation of anaerobic pathogenic bacteria. Periodontal diseases are group of conditions, including gingivitis and periodontitis, which affect the supporting structures of the teeth such as gums, periodontal ligaments, alveolar bone, and dental cementum. It is a localised inflammatory response caused by bacterial infection of a periodontal pocket associated with subgingival plaque (2). Although the bacteria are the primary cause, the expression of microbial pathogenic factors alone may not be sufficient to cause periodontitis but they initiate damage directly or indirectly by triggering host-mediated responses that lead to self-injury. This disease caused by bacterial infection of a periodontal pocket arising from the accumulation of subgingival plaque and inflammatory response, which can result in tooth loss (3). Various intra-pocket drug delivery systems have been proposed, including fibers, strips, films, injectable gels, and micro particles (4). Periodontitis cannot be cured, but it can be arrested. It can be localized or generalized and depending on the amount of clinical attachment loss, the severity of the disease process is labelled as mild (< 3mm) moderate (3-4mm) or severe (5mm). The local drug delivery to be effective, it must meet three requirements: It must: (a) reach the sites of disease activity namely the base of the pocket (b) be delivered at a bacteriostatic bactericidal concentration and (c) remain in place long enough to be effective.

Many polymer-based intra-pocket devices containing drugs for this treatment had been studies as tetracycline loaded into poloxamer and monoglycerides (6). Tetracycline-loaded bioadhesive semisolid, polymeric system based upon hydroxyethylcellulose and polyvinyl pyrrolidone (8) and Metronidazole-loaded systems based upon Carbopol 974P, hydroxyl ethyl cellulose and polycarbophil (7) revealed significant results. Tetracycline base loaded into the micro tubular excipient halloysite and coated with chitosan to further retard the drug release (9). Intra-pocket delivery devices in the periodontal pocket are of following types such as fibres (10) strips (11) films (12) and injectable gels (13). The various drugs were utilised for periodontal therapy such as chlorhexidine, tetracycline, minocycline and metronidazole. The reason behind this apparent omission is of interest in the context of local delivery approach. The effectiveness of dental drugs has been generally evaluated only for conventional modes. To improve this method of drug administration the aims and optimal duration of treatment need to be further clarified so that development of delivery system can occur through modification of the devices release and degradation characteristics.

**Experimental**

**Material**

Doxycycline hyclate was obtained as a gift samples from Zydus cadila healthcare Pvt. Ltd Ahmadabad, India. Pluronic F127 and Zinc oxide was purchased from Rankem chemicals Mumbai India, N-methyl-2-spyrolidione the other materials such as sodium hydroxide, Potassium dihydrogen phosphate, sodium chloride, calcium chloride, hydrochloric acid, methanol was purchased from Loba chemicals, Pvt. Ltd Mumbai India. Double distilled water was used throughout the study.

**Methods**

**Physiochemical Compatibility Studies of Drug and Polymer**

**Differential Scanning Calorimetry (DSC)**

The melting temperature of drug was determined using capillary method and confirmed by differential scanning calorimetry (DSC). Thermogram of DH was obtained using DSC (DSC 822c, Mettler Toledo). To check Drug-Polymer interaction study by DSC the drug and polymer taken then hermetically sealed in perforated aluminium pans and
heated at constant rate of 10 °C/min over the temperature ranges of 35-300 °C.

**Calibration Curve in pH 7.4 Phosphate Buffer**

10 mg of DH was dissolved in 100 mL of pH 7.4 buffers to obtained working standard of 100 μg/mL Aliquots of 0.4 mL to 2.8 mL from the stock solution representing 04 to 28 μg/mL of drug transferred to 10 mL volumetric flask and also the volume was adjusted to mark. Absorbance of the above solution was taken at 273 nm by UV spectrophotometer (1700, Shimadzu, Japan) against the blank solution prepared in the same manner without adding the drug. A graph of absorbance Vs concentration was plotted from above obtained readings.

**Formulation and development**

**A) Preparation of in situ-gel**

Formulations were prepared on a weight basis using a cold process. Carefully a weighed amount of pluronic F127 sufficient to yield was slowly added to cold water (5°C). DH was added with a constant stirring, the dispersion was then refrigerated until a clear solution was formed (i.e. upto 5 h). Active substances like zinc oxide which is insoluble in water was dissolved prior to addition in N-methyl 2-pyrolidone (5°C) to form a homogeneous mass. Then prepared formulations were stored in well closed amber coloured container until it is used. Following

![Figure 1. Bacteria in subgingival plaque have caused a periodontal pocket to develop, inflaming surrounding tissue and causing loss of alveolar bone (5).](image)

**Table 1. Composition of in situ gel containing DH.**

| Sr No. | Formulation Code | Doxycycline hyclate(%w/w) | Pluronic F127(%w/w) | NMP(%w/w) | ZnO(%w/w) | Purified Water (mL) |
|--------|------------------|--------------------------|--------------------|-----------|-----------|-------------------|
| 1      | F1               | 5                        | 18                 | -         | -         | q.s               |
| 2      | F2               | 5                        | 19                 | -         | -         | q.s               |
| 3      | F3               | 5                        | 20                 | 10        | -         | q.s               |
| 4      | F4               | 5                        | 20                 | 20        | -         | q.s               |
| 5      | F5               | 5                        | 20                 | 30        | -         | q.s               |
| 6      | F6               | 5                        | 20                 | 20        | 0.1       | q.s               |
| 7      | F7               | 5                        | 20                 | 20        | 0.2       | q.s               |
| 8      | F8               | 5                        | 20                 | 20        | 0.3       | q.s               |
| 9      | F9               | 5                        | 20                 | 20        |           | q.s               |

Characterization and Evaluation of the Formulations.
batches were developed which contain the appropriate concentration of drug and various concentration of excipients.

**Physical properties**

The appearances of formulations were inspected by visual observation. The observed clarity and colour of formulated gel was determined by visual inspection under black & white background.

**Drug content**

Formulations containing 1 mg drug was taken in 10 mL volumetric flask dissolved in methanol then made up the volume to 10 mL then filtered. Absorbance values were measured by UV-spectrophotometer (1700, Shimadzu, Japan) at $\lambda_{\text{max}}$ 273 nm. Concentrations of drug were calculated from the standard calibration curve prepared in methanol to get the drug content (14).

$$\text{Amount of drug} = \frac{A_s \times G_L}{G_r}$$

Where, $A_s$: absorbance of sample solution, $G_L$: conc. of drug in standard solution, $G_r$: absorbance of standard drug solution.

**Surface pH**

An acidic or alkaline formulation was bound to cause irritation on mucosal membrane and hence this parameter assumes significance while developing a mucoadhesive formulation. A digital glass electrode pH meter was used for this purpose. pH was noted by dipping the electrode in to the formulations and allow to equilibrating for 1 min (15).

**Gelation & Gel melting temperature**

Typically, the determination of the boundary between the sol and gel phases depends on the selected experimental method. In this study a
simple test-tube inverting method was employed to roughly determine the phase boundary. Gelation and gel melting temperatures were assessed using a modification of the Miller and Donavan technique. A 5 mL aliquot of gel was transferred to test tubes and immersed in a thermostat water bath at 4 °C, and sealed with aluminium foil. The temperature was increased with the increments of 1 °C and left to equilibrate for 1 min at each new setting. The samples were then examined for gelation, which was said to have occurred when the meniscus would no longer move upon tilting through 90 °C. The gel melting temperature, the temperature at which a gel started flowing upon tilting through 90 °C, was recorded (16).

**Rheological study**

Viscosities of formulations before and after gelation were measured by using Brook field DV-E viscometer using Spindle number-3 at 100 rpm shear rate. In case of Pluronic F127 based systems the viscosity was recorded at increasing temperature in range of 20 °C to 30 °C and graphs were plotted. From which an approximate gelation temperature was determined as indicated by sudden rise of viscosity (17).

**Syringeability study**

All the developed formulations were tested by using 21-gauge needle for the intention whether the formulations passes through it (8).

---

### Table 2. Evaluation of formulations.

| Formulation code | Visual Appearance | pH (Mean ± SD) | Gel Melting (Mean ± S.D.) | Viscosity (Mean ± S.D.) | Drug Content (Mean ± S.D.) |
|------------------|-------------------|----------------|--------------------------|------------------------|---------------------------|
| F1               | Transparent       | 4.58 ± 0.02    | 86.7 ± 0.3               | 35912 ± 1.7            | 94.21 ± 2.98              |
| F2               | Transparent       | 4.65 ± 0.03    | 85.2 ± 0.6               | 36278 ± 1.0            | 92.17 ± 2.12              |
| F3               | Transparent       | 4.67 ± 0.04    | 84.5 ± 0.2               | 37294 ± 2.3            | 92.90 ± 3.43              |
| F4               | Transparent       | 4.82 ± 0.08    | 82.8 ± 0.3               | 35576 ± 2.9            | 91.43 ± 2.73              |
| F5               | Transparent       | 4.90 ± 0.03    | 80.5 ± 0.2               | 34785 ± 0.9            | 91.90 ± 3.20              |
| F6               | Transparent       | 4.97 ± 0.05    | 79.4 ± 0.5               | 32991 ± 1.3            | 89.74 ± 3.77              |
| F7               | Transparent       | 5.16 ± 0.07    | 78.5 ± 0.4               | 33552 ± 1.5            | 89.98 ± 2.57              |
| F8               | Transparent       | 5.22 ± 0.01    | 77.3 ± 0.4               | 34216 ± 3.6            | 88.56 ± 3.12              |
| F9               | Transparent       | 5.38 ± 0.02    | 75.8 ± 0.6               | 34510 ± 1.4            | 87.15 ± 2.45              |

**Mucoadhesive Strength**

The mucoadhesive potential of each formulation was determined by measuring the force required to detach the formulation from sheep intestinal membrane using a modified physical balance method; results were shown in Figure 4. In brief, intestinal membrane was carefully removed from the intestinal cavity of sheep obtained from the local slaughterhouse. Tissues were immediately used after separation. At the time of testing, a section of intestinal membrane tissue was secured (keeping the mucosal side out) to the upper probe using a cyanoacrylate adhesive. The surface area of each exposed mucosal membrane was 4.2 cm². At room temperature, fixed amount of samples of each formulation were placed on the lower probe. The probes were equilibrated. Probe with intestinal tissue was lowered until the tissue contacted the surface of the sample. Immediately, a slight force was applied for 2 min. to ensure intimate contact between the tissue and the sample. The mucoadhesive force, expressed as the detachment stress in dyne/cm², was determined from the minimal weights that detached the tissues from the surface of each formulation using the following equation (13).

\[
\text{Detachment Stress (dyne/cm}^2\text{)} = \frac{mg}{A}
\]
Where, \( m \) - The weight added to the balance in grams, \\
\( g \) - The acceleration due to gravity taken as \( 980 \, \text{cm/s}^2 \) \\
\( A \) - Surface area of sheep intestinal mucosa

**In-vitro drug release study**

The release studies were performed using the dialysis method. Typically 1g of pluronic F127 gel was placed in a dialysis tube (having MW 12000 Daltons). The dialysis tube (having 2.3cm in diameter) was then placed in a vessel containing 100 mL of buffer solution pH 7.4, (simulated pH of GCF) stirred at 100 rpm. Samples were collected periodically and replaced with fresh medium of phosphate buffer pH 7.4. After filtration through the Whatman filter paper no. 41, the concentration of DH was determined by UV-spectrophotometry method 273nm.

**Anti-microbial activity**

The antimicrobial efficiency and prolonged effect of selected controlled release Doxycycline hyclate \textit{in-situ} gel were determined on \textit{S. aureus}, \textit{E. coli}, and \textit{C. albicans} strains as a function of time. The inhibitory effect of formulation on the studied microorganisms was evaluated using agar well diffusion test. Wells were punched into the nutrient agar previously seeded with test organisms and they were filled with 100 \( \mu \)L of the samples. After allowing diffusion of solution for 2 h the plates were incubated for 24 h at 37 \( ^{\circ} \text{C} \) and the diameters of inhibition zones were measured. The inhibitory effect of optimized gel formulation was compared with marketed Doxycycline hyclate dental gel (20).

### Table 3. In-vitro diffusion study data of gel formulations (F1-F3) (\( n = 3 \pm \text{S.D.} \)).

| Time (h) | % Cumulative drug release (Mean ± S.D.) |
|---------|----------------------------------------|
|         | F1                  | F2                    | F3                    |
| 0       | 0                   | 0                     | 0                     |
| 0.3     | 6.29 ± 1.3          | 6.05 ± 1.1            | 5.91 ± 1.4            |
| 1       | 13.93 ± 1.9         | 13.22 ± 2.1           | 12.85 ± 2.1           |
| 2       | 22.97 ± 1.3         | 22 ± 1.3              | 21.17 ± 3.0           |
| 4       | 36.43 ± 2.4         | 35.78 ± 2.4           | 35 ± 2.5              |
| 6       | 49.56 ± 2.1         | 48.92 ± 1.7           | 48.24 ± 2.8           |
| 8       | 67 ± 2.7            | 66 ± 2.9              | 65.21 ± 1.4           |
| 10      | 84 ± 2.4            | 82.12 ± 2.5           | 81.16 ± 1.9           |
| 12      | 96.29 ± 1.8         | 95.87 ± 1.7           | 94.98 ± 2.3           |

**Figure 4.** Mucoadhesive force data of gel formulations.
Results and Discussions

Results

Melting point of DH was measured; and found to be in the range of 205-208 °C. It was confirmed with the reported melting point of DH. It was also confirmed by differential scanning calorimetry at scanning rate of 10 °C/min and it exhibits a sharp melting endothermic peak at temperature of 207.64 °C.38

Drug polymer compatibility study of pure drug, drug-polymer physical mixtures were analyzed by IR spectroscopy and Differential Scanning Calorimetry indicates that there were no interaction between the excipients added and drug hence suitable for formulations. The thermogram of physical mixture of DH and Pluronic F-127; ratio of 1:1 were taken which showed no shifting in the thermograms proving that there were no drug-polymer interaction.

Formulations were prepared using cold method. Antibacterial drug such as DH was used in the formulations. Total nine batches were prepared in Batch B1, B2 only the pluronic was used in the various concentrations, but according to their physical appearance, gelation and sol to gel formation phenomenon only 20% w/w was considered as an optimum concentration. Formulations B4, B5 and B6 were prepared by utilizing NMP at a range of 10 & 30% concentration, but 20% w/w was found to be best concentration and therefore was selected for further studies. NMP was added because it forms los viscous solution in presence of polymer.

Formulations containing xanthan gum viz., B3, B6, and B9 were prepared in concentration

In-vitro drug release profile provides insight into the efficiency of the drug delivery system proposed for the controlled release of drug. The drug release profile was tested in phosphate buffer solution pH 7.4 to imitate the environment of periodontitis. Systems containing 5%w/w DH & 20%w/w Pluronic F127 showed a release of drug 45% in the period of 5 h. It has been suggested that Pluronic F127 might retard the release of drug since the structure of the gel functioned as barrier to the release of drug.

The influence of NMP on release of drug from the formulation containing 20% w/w Pluronic F127 and DH was also investigated. The added 20%w/w NMP into the gel systems enhanced the release of DH. This result signified that NMP might be decrease the gel strength of the formulation.

DH released from formulation shows a biphasic characteristic, with a relatively fast release at the initial hours and then release of drug was almost completed. The amount of drug released from the same batch was found to be 90% at the end of 12 h.

Table 3. In-vitro diffusion study data of gel formulations (F1-F3) (n = 3 ± S.D).

| Time (h) | F1  | F2  | F3  |
|---------|-----|-----|-----|
| 0       | 0   | 0   | 0   |
| 0.3     | 6.29 ± 1.3 | 6.05 ± 1.1 | 5.91 ± 1.4 |
| 1       | 13.93 ± 1.9 | 13.22 ± 2.1 | 12.85 ± 2.1 |
| 2       | 22.97 ± 1.3 | 22 ± 1.3 | 21.17 ± 3.0 |
| 4       | 36.43 ± 2.4 | 35.78 ± 2.4 | 35 ± 2.5 |
| 6       | 49.56 ± 2.1 | 48.92 ± 1.7 | 48.24 ± 2.8 |
| 8       | 67 ± 2.7 | 66 ± 2.9 | 65.21 ± 1.4 |
| 10      | 84 ± 2.4 | 82.12 ± 2.5 | 81.16 ± 1.9 |
| 12      | 96.29 ± 1.8 | 95.87 ± 1.7 | 94.98 ± 2.3 |

Table 4. In-vitro diffusion study data of gel formulations (F4- F6) (n = 3 ± S.D).

| Time (h) | F4   | F5   | F6   |
|---------|------|------|------|
| 0       | 0    | 0    | 0    |
| 0.3     | 5.51 ± 1.4 | 5.12 ± 1.0 | 4.9 ± 1.4 |
| 1       | 12.16 ± 1.2 | 11.8 ± 1.8 | 11.54 ± 2.1 |
| 2       | 21.37 ± 2.1 | 21 ± 2.2 | 20.87 ± 2.4 |
| 4       | 34.56 ± 1.8 | 33.26 ± 1.4 | 32.79 ± 3.2 |
| 6       | 47.47 ± 2.4 | 46.34 ± 3.0 | 45.15 ± 1.9 |
| 8       | 64.9 ± 3.1 | 64.43 ± 2.3 | 63.27 ± 1.7 |
| 10      | 79.04 ± 2.6 | 77.82 ± 2.7 | 75.88 ± 2.1 |
| 12      | 93.51 ± 1.8 | 92.97 ± 2.4 | 92.21 ± 2.3 |

Figure 5. In-vitro diffusion study formulations F1-F3.
0.1 to 0.3% w/v. Optimum concentration 0.3% w/v was found to be best. pH of formulations was adjusted between 6.2 to 6.8 pH; by using phosphate buffer. The formulations were filled in 10 mL amber colored glass vials, capped with rubber bungs and sealed with aluminium caps. Formulations were stored in a refrigerator (4–8 °C) until use. The prepared in situ gels containing Doxycycline hyclate was found to be transparent, clear and the colour of formulation was found to be transparent. The drug content of the formulation was found to be in the range of 87.15% and 94.21%. So, on that basis we can say that the drug was uniformly distributed throughout the formulations.

The speed and extent of gelation for all formulations were determined. The temperature taken to form the gel was in the range of 30.6 to 37.4 °C. Physically, gel formation is related to micellar packing and volume fraction. Researchers have attributed gelation to the dehydration of PPO groups in the micelle core, a change in the micellar volume or a decrease in the critical micelle concentration and an increase in the aggregation number (18). The finding that tetracycline lowered the gelation temperature was similar to the result reported by Esposito et al., 1996 (6). This feature was tentatively explained by a facilitation of the interaction between the hydrophobic portion of the polymer molecules, which could disrupt the micellar structure and increase the entanglement of micelles. Pisal et al., 2004 have also reported a significant decrease in

| Time (h) | F7          | F8          | F9          |
|---------|-------------|-------------|-------------|
| 0       | 0           | 0           | 0           |
| 0.3     | 4.67 ± 1.4  | 4.11 ± 1.7  | 3.83 ± 2.1  |
| 1       | 11.07 ± 1.8 | 10.87 ± 2.3 | 10.04 ± 1.9 |
| 2       | 20.31 ± 1.6 | 21.43 ± 2.6 | 18.67 ± 1.5 |
| 4       | 32.06 ± 2.1 | 31.6 ± 1.4  | 29.23 ± 1.1 |
| 6       | 43.74 ± 3.1 | 42.95 ± 1.7 | 40.21 ± 2.7 |
| 8       | 62.63 ± 2.7 | 62.13 ± 2.9 | 58.43 ± 3.1 |
| 10      | 76.33 ± 2.4 | 75.13 ± 2.1 | 69.94 ± 1.4 |
| 12      | 91.38 ± 1.5 | 89.24 ± 1.8 | 88.16 ± 2.2 |
gelation temperature by vitamin B12 at all concentrations of pluronic F 127, attributed to the higher water solubility of vitamin B12. The presence of vitamin B12 predominantly decreased the critical micellar concentration and increased the micellar aggregation (19). While the temperature required for melting the gel containing NMP was found to be in the range of 82.8 to 79.4 for 10 to 30% NMP. While the ZnO concentration increases 0.1 to 0.3%, it was found that both the gelation temperature and gel melting temperature decreased from 26.3 to 22.5 and 78.5 to 75.8.

The apparent viscosity values were measured for liquid formulations and gel using Brookfield viscometer DV-E with spindle no. 3 at 100 rpm. The marked increase in viscosity of the in situ gel formulations was increased from 6421.0 to 6978.9 cps as the Pluronic F 127 concentration was increased from 10 to 30%. It was also seen that the viscosity of the gel formulation was decreased from 6379.3 to 6032.7 cps as the concentration of NMP increased from 10 to 30%. While addition of ZnO, it was directly proportional to the viscosity of gel formulations i.e., increase in the concentration of ZnO gradually increases the viscosity of gel formulations i.e from 6165.0 to 6187.1 cps; was found to be in proportionate with the increasing polymer concentration.

All the prepared formulations were found to be syringeable through 21-gauge needle. Results revealed that all the formulations (F1-F9) were found to be syringeable at cold temperature.

Table 6. Anti-bacterial and anti-fungal activity data of gel formulations (n = 3 ± S.D).

| Sr. no | Batches | Inhibition zone (mm) (Mean ± S.D.) |
|--------|---------|-----------------------------------|
|        |         | S. Aureus | E. Coli | C. Albicans |
| 1      | F1      | 11.5±0.2  | 10.3±0.3 | 9.3±0.2     |
| 2      | F2      | 10.7±0.5  | 9.4±0.6  | 8.9±0.6     |
| 3      | F3      | 10.3±0.7  | 9.5±0.4  | 8.4±0.3     |
| 4      | F4      | 11.2±0.8  | 9.2±0.7  | 8.3±0.6     |
| 5      | F5      | 11.4±0.5  | 9.6±0.2  | 7.5±0.7     |
| 6      | F6      | 10.7±0.4  | 9.7±0.5  | 7.1±0.5     |
| 7      | F7      | 21.9±0.6  | 18.8±0.7 | 16.3±0.6    |
| 8      | F8      | 24.4±0.1  | 21.9±0.9 | 19.7±0.4    |
| 9      | F9      | 27.7±0.7  | 24.5±0.7 | 20.2±0.7    |
Mucoadhesive Strength (MS) of various formulations was carried out; mainly to select the polymer proportion and total polymer concentration for the prepared gels. The results of mucoadhesive strength measurement by modified physical balance method are shown in Figure. 8. It was found that, as the total concentration of polymers (Pluronic F-127) increased, the mucoadhesive strength (MS) was found to increase. The mucoadhesive material must come in close contact with the tissue for the mucoadhesion. Pluronic F127, due to their chemical nature, is high-molecular-weight polymer that readily swells in water; the swelling exposes a large adhesive surface for maximum contact with the mucosa (the glycoprotein predominant in the mucous layer) and, thus, provides excellent mucoadhesion. The stronger the bioadhesive force more is the residence time. But if the mucoadhesion is too strong the gel can damage the mucosal membrane. In this study, it was found that as the concentration of NMP increased from 10 to 30% the MS of the prepared gel decreased profoundly mainly because of the solvent nature of NMP which decreases both the viscosity and the MS. The effect of ZnO over the MS was not much significant which can be shown in Figure.

In-vitro drug release profile provides insight into the efficiency of the drug delivery system proposed for the controlled release of drug. The drug release profile was tested in phosphate buffer solution pH 7.4 to imitate the environment of periodontitis. Systems containing 5 %w/w DH & 20%w/w Pluronic F127 showed a release of drug 45% in the period of 5 h. It has been suggested that Pluronic F127 might retard the release of drug since the structure of the gel functioned as barrier to the release of drug.

The influence of NMP on release of drug from the formulation containing 20% w/w Pluronic F127 and DH was also investigated. The added 20%w/w NMP into the gel systems enhanced the release of DH. This result signified that NMP might be decrease the gel strength of the formulation.

DH released from formulation shows a biphasic characteristic, with a relatively fast release at the initial hours and then release of drug was almost completed. The amount of drug released from the same batch was found to be 90% at the end of 12 h.

**Drug release kinetics**

**Model fitting to drug release profile (18)**

The release constant was calculated from the slope of the appropriate plots, and the regression coefficient ($R^2$) was determined. It was found that the in-vitro drug release of formulation was best explained by zero order, as the plots showed the highest linearity.

| Formulation code | $R^2$      | Best fit model          |
|------------------|------------|-------------------------|
|                  | Zero order | First order | Higuchi model |             |
| F1               | 0.995      | 0.862      | 0.953        | Zero order  |
| F2               | 0.996      | 0.860      | 0.951        | Zero order  |
| F3               | 0.997      | 0.872      | 0.949        | Higuchi model |
| F4               | 0.997      | 0.890      | 0.950        | Higuchi model |
| F5               | 0.997      | 0.890      | 0.947        | Zero order  |
| F6               | 0.996      | 0.889      | 0.945        | Zero order or Higuchi model |
| F7               | 0.996      | 0.899      | 0.941        | Zero order or Higuchi model |
| F8               | 0.995      | 0.919      | 0.944        | Zero order or Higuchi model |
| F9               | 0.995      | 0.898      | 0.931        | Zero order or Higuchi model |
Mechanism of drug release

The corresponding plot of (log cumulative percent drug release Vs log time) of the Korsmeyer-Peppa’s equation indicated a good linearity of regression.

Discussion

To improve this method of drug administration the aims and optimal duration of treatment needs to be further clarified so that development of delivery system can occur through modification of the device’s release and degradation characteristics. In Situ gels so prepared and characterized for its physical properties, drug content, pH, gelation properties, gelation strength, rheology, syringeability, mucoadhesion, anti-microbial activity, in-vitro drug release study, and their kinetic rate profile. Physical appearance of formulations was found to be clear and transparent.

The drug content of formulation was found to be satisfactory in the ranges of 87.15 to 94.21%. The pH of formulations was found to be in the ranges of 4.58 to 5.38. Gelation and gel melting temperature of formulations was found to be in the ranges of 22.5 to 37.4 °C and 75.8 to 86.7 °C, respectively. Viscosity of formulations was found to be in the ranges of 32991 to 37294 cps. All the prepared formulations were found to be syringeable through 21-gauge needle. Mucoadhesive strength of formulations was found to be in the ranges of 3889 to 4186 dyne/cm². Results of antimicrobial activity was found to be against *S. Aureus* in the ranges of 10.3 to 27.7 mm, *E.Coli* in the ranges of 9.2 to 24.5 mm and *C. Albicans* 7.1 to 20.2 mm respectively. In-vitro drug release profile was found to be in the ranges of 88.16 to 96.29% at the end of 12 h. The model fitting to drug release profile was zero order for F1, F2 and F5 batch, Higuchi model for F3-F4 batch and zero order or higuchi model for F6-F9 batch. The

![Figure 8. Zero order kinetic profile.](image)

**Table 8. Mechanism of drug release data of gel formulations.**

| Formulation code | Korsmeyer-peppas model | Mechanism                  |
|------------------|-------------------------|----------------------------|
|                  | ‘k’ value   | ‘n’ value   | R²          |                        |
| F1               | 1.154       | 0.738       | 0.995       | Anomalous (Non-Fickain) transport |
| F2               | 1.137       | 0.749       | 0.994       | Anomalous (Non-Fickain) transport |
| F3               | 1.126       | 0.754       | 0.994       | Anomalous (Non-Fickain) transport |
| F4               | 1.108       | 0.768       | 0.995       | Anomalous (Non-Fickain) transport |
| F5               | 1.189       | 0.783       | 0.995       | Anomalous (Non-Fickain) transport |
| F6               | 1.077       | 0.788       | 0.996       | Anomalous (Non-Fickain) transport |
| F7               | 1.061       | 0.800       | 0.995       | Anomalous (Non-Fickain) transport |
| F8               | 1.041       | 0.820       | 0.995       | Anomalous (Non-Fickain) transport |
| F9               | 1.004       | 0.832       | 0.995       | Anomalous (Non-Fickain) transport |
An approach to Improve Therapeutic Efficacy of Doxycycline Hyclate in Treatment of Periodontitis

cps. All the prepared formulations were found to be syringeable through 21-gauge needle. Mucoadhesive strength of formulations was found to be in the ranges of 3889 to 4186 dyne/cm². Results of antimicrobial activity was found to be against S. Aureus in the ranges of 10.3 to 27.7 mm, E.Coli in the ranges of 9.2 to 24.5 mm and C. Albicans 7.1 to 20.2 mm respectively. In-vitro drug release profile was found to be in the ranges of 88.16 to 96.29% at the end of 12 h. The model fitting to drug release profile was zero order for F1, F2 and F5 batch, Higuchi model for F3-F4 batch and zero order or higuchi model for F6-F9 batch.

The mechanism of drug release was anomalous (non-fickain) transport for all the prepared batches. From the aforesaid studies, formulation F8 was optimized and further subjected for texture analysis for studying the hardness, compressibility, adhesiveness, cohesiveness, and DSC. Formulated in situ gels F6 showed the effective pH, gelation, viscosity, gel strength, and drug release properties along with good mucoadhesive strength. The drug release mechanism from the gel matrices was found to be anomalous and following the Zero order and also gives the satisfactory result of Texture analysis and DSC. The results of present study clearly indicated promising potential of in situ gel containing Doxycycline Hyclate for delivering drug to infected periodontal pockets and could be viewed as alternative to conventional dosage form.

In conclusion, the formulated in situ gel as a drug delivery system promising the approach which are utilised for improving therapeutic efficacy of Doxycycline hydroclate in the treatment of periodontitis. The use of Pluronic F127 as well as NMP showed better drug release profile at the end of 12 h, ZnO showing a better antibacterial activity. Once administered, the solvent diffuses out leading to the formation of depot for controlled delivery of active ingredient. The concentration of polymer, type of solvent, and additives used affect release rate of drug from depot formed in situ. Inclusion of ZnO also improve therapeutic efficacy of formulation in the management of periodontitis. Hence, in future such type of drug delivery system may utilise for the periodontal treatment.

Acknowledgement

The authors would like to acknowledge the Principal, Institute of Pharmaceutical Education and Research Shirpur, for providing the necessary facilities to carry out the research work.

References

(1) Sapra P, Patel BD, Patel DV and Borkhataria CH. Review. Recent advances in periodontal formulations. Int. J. Pharm. Chem. Anal. (2014)1: 65-74.
(2) Haffajee AD and Socransky SS. Attachment level changes in destructive periodontal diseases. J. Clin. Periodontol. (1986) 13: 461-72.
(3) Schwach AK, Vivien CN and Gunny R. Local delivery of antimicrobial agents for the treatment of periodontal diseases. Eur. J. Pharm. Biopharm. (2000)50: 83-99.
(4) Jain N, Jain GK and Javed S. Recent approaches for the treatment of periodontitis. Drug Discov. Today (2008) 13: 932-43.
(5) Katiyar A, Prajapati SK, Akhtar Ali, Gautam A and Vishwakarma S. Therapeutic strategies for the treatment of periodontitis. IRJP (2012) 3: 61-7.
(6) Esposito E, Carotta V and Scabbia A. Comparative analysis of tetracycline-containing dental gels: poloxamer- and monoglyceridebased formulations. Int. J. Pharm. (1996) 23:142-9.
(7) Jones DS, Woolfson AD, Brown AF and O’Neill MJ. Mucoadhesive, syringeable drug delivery system for controlled application of metronidazole to the periodontal pocket: in vitro release kinetics, syringeability, mechanical and mucoadhesive properties. J. Control Rel. (1997) 9: 71.
(8) Jones DS, Woolfson AD and Djokic J. Development and mechanical characterization of bioadhesive semi-solid, polymeric systems containing tetracycline for the treatment of periodontal diseases. Pharm. Res. (1996) 13: 1734-8.
(9) Maheshwari M, Paradkar A and Yamamura S. Preparation and Characterization of Pluronic-Colloidal Silicon Dioxide Composite Particles as Liquid Crystal Precursor. AAPS Pharm. Sci. Tech. (2006) 7: E1-E7.
(10) Tonetti MS, Pini-Prato G and Cortellini P. Principles and clinical applications of periodontal controlled drug delivery with tetracycline fibers. Int. J. Periodontol. Res. Dent. (1994) 14: 421-35.
(11) Addy M and Langeroudi M. Comparison of the immediate effects on the sub-gingival microflora of acrylic strips containing 40% chlorhexidine, metronidazole or tetracycline. J. Clin. Periodontol. (1984) 11: 379-86.
(12) Golomb G, Friedman M and Soskolne A. Sustained release device containing metronidazole for periodontal use. J. Dent. Res. (1984) 63: 1149-53.
(13) Bruschi ML, Jones DS and Panzeri H. Semisolid systems containing propolis for the treatment
of periodontal disease: in-vitro release kinetics, syringeability, rheological, textural, and mucoadhesive properties. J. Pharm. Sci. (2007) 96: 2074-89.

(14) Gorle A and Gattani S. Development and evaluation of ocular drug delivery system. Pharm. Dev. Tech. (2010) 15: 46-52.

(15) Bottenberg P, Cleymaet R and Muynck CP. Development and testing of bioadhesive fluoride containing slow release tablets for oral use. J. Pharm. Pharmacol. (1991) 43: 457-64.

(16) Miller SC and Donovan MD. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int. J. Pharm. (1982) 12: 147-52.

(17) Edsman K, Carlfors J and Petersson R. Rheological evaluation of poloxamer as an in situ gel for opthalmic use. Eur. J. Pharm. Sci. (1998) 6: 105-12.

(18) Gorle AP and Gattani SG. Design and evaluation of polymeric ocular drug delivery system. Chem. Pharm. Bull. (2009) 57: 914-9.

(19) Pisal SS, Paradkar AR, Mahadik KR and Kadam SS. Pluronic gels for nasal delivery of Vitamin B12 Part I: preformulation study. Int. J. Pharm. (2004) 37: 270-4.

(20) O’Donnell F, Smyth TJP, Ramachandran VN and Smyth WF. A Study of the anti-microbial activity of selected synthetic and naturally occurring quinolines. Int. J. Antimicro. Ag. (2010) 35: 30-8.

This article is available online at http://www.ijpr.ir